Cardiovascular risk management among 1806 low risk patients in a primary care setting

Canadian Journal of Cardiology

Volumn 12, Issue 9, 1996, Pages 797-801

  Teo, K K ^a,c,d   Makinen, Drew ^b,c   Montague, Patricia ^c   Taher, Taha ^c   Barnes, Marion ^c   Montague, Terrence ^c,c,d   Dowding, Glennora ^c   Bay, Kyung ^c,d   Yim, Rita ^d   Catellier, Diane ^d   Dealmeida, Joseph ^d  

^a UNIVERSITY OF ALBERTA HOSPITAL   (Canada)

^b RJA Medicentres   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

^d UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Cardiovascular risk management; Low risk patients; Patterns of practice

Indexed keywords

LIPID;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DYSLIPIDEMIA; FEMALE; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MEDICAL AUDIT; PREVALENCE; PRIMARY MEDICAL CARE; RISK MANAGEMENT;

EID: 10544238109     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.18549/PharmPract.1996.1.2637     Document Type: Article

References (24)

1. Montague TJ, Taylor LK, Barnes ME, et al, for the CQIN Investigators. Can practice patterns and outcomes be successfully altered? Examples from cardiovascular medicine. Can J Cardiol 1995;11:487-92.
2. Montague TJ, Tsuyuki RT, Burton JR, Dzavik V, William, R, Teo KK. Prevention and regression of coronary atherosclerosis Is it safe and efficacious therapy? Chest 1994;105:718-26.
3. Superko HR, Krauss RM. Coronary artery disease regression. Convincing evidence for the benefit of aggressive lipoprotein management. Circulation 1994;90:1056-69.
4. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet 1994;344:1383-9.
5. Roberts WC. Getting cardiologists interested in lipids. Am J Cardiol 1993;72:744-5.
6. Stevenson J, Godstand IF, Wynn V. Cardiologists rebuked. Lancet 1994;344:1557. (Lett)
7. The Clinical Quality Improvement Network (CQIN) Investigators. Low incidence of assessment and modification of risk factors in acute care patients at high risk for cardiovascular events, particularly among females and the elderly. Am J Cardiol 1995;76:570-3.
8. Davey Smith G, Song F, Sheldon TA. Cholesterol lowering and mortality: the importance of considering initial level of risk. BMJ 1993;306:367-73.
9. Davey Smith G, Pekkanen J. Should there be a moratorium on the use of cholesterol lowering drugs? BMJ 1992;304:431-4.
10. Canadian Consensus Conference on Cholesterol. The Canadian Consensus Conference on the prevention of heart and vascular disease by altering serum cholesterol and lipoprotein risk factors: Final report. Can Med Assoc J 1988;139(Suppl 11 ):1-8.
11. Expert Panel on Detection, Evaluation and treatment of high blood cholesterol in adults. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). JAMA 1993;269:3015-23.
12. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
13. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;327:685-91.
14. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left venticular dysfunction after myocardial infarction. N Engl J Med 1992;327:669-77.
15. Montague TJ, Yusuf S, Tsuyuki RT, Teo KK. Importance of preventing ischemia in patients with congestive heart failure. Can J Cardiol 1993;9(Suppl F):39F-43F.
16. Joffres MR, Titanich KLC, Hessel PA. The Alberta Heart Health Survey: Methods and results. Can J Cardiol 1993;9:300-8.
17. Neighbor WE, Scott CS, Schaad DC, Macdonald SC, Van Citters R. Assessment and counselling of coronary risk factors by family practice residents. J Fam Pract 1991;32:273-81.
18. Robinson MK, DeHaven MJ, Wallace JB, Fost T. Hypercholesterolemia: Case finding in family practice. South Med J 1992;85:1091-5.
19. Hudson J, Keefe C, Hogan A. Cholesterol measurement and treatment in community practice. J Fam Pract 1990;31:139-44.
20. Ackman M, Tsuyuki R, Kornder J, et al, for the CQIN Investigators-Practice patterns and outcomes in 4606 patients with congestive heart failure. Can J Cardiol 1995;11(Suppl E):58E.
21. Ackman M, Tsuyuki R, Kornder J, et al, for the CQIN Investigators Patterns of anticoagulation and antiplatelet prophylaxis in 1691 patients with atrial fibrillation. Can J Cardiol 1995;11(Suppl E):244E.
22. Sheperd J, Cobbe S, Ford I, et al, for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-7.
23. The Canadian Cardiovascular Collaboration for the Heart Outcomes Prevention Evaluation (HOPE) Trial. Protocol of a trial to evaluate ramipril and vitamin E on clinically important vascular end points in high risk patients. Unpublished protocol, available from authors. Medical Research Council and Hoechst Ltd, Canada, 1993.
24. The Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT) Investigators. Protocol of a trial to evaluate lipid lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis progression and regression in clinically high risk patients with normal cholesterol levels. Unpublished protocol, available from authors. Medical Research Council and Merck Frosst Inc, Canada, 1991.